Home » Abbott’s Humira Approved in Europe for Expanded Treatment of Crohn’s Disease
Abbott’s Humira Approved in Europe for Expanded Treatment of Crohn’s Disease
Abbott Thursday announced that the European Commission (EC) has approved Humira (adalimumab) for the treatment of moderately active Crohn’s disease (CD) in adult patients who have had an inadequate response to conventional therapy.
Equities.com
Equities.com
Upcoming Events
-
07May
-
14May
-
30May